StephanieRHuang

R. Stephanie Huang, PhD

Assistant Professor of Medicine, Section of Hematology/Oncology

Dr. R. Stephanie Huang is a junior faculty member in the Section of Hematology/ Oncology in the Department of Medicine. She is also a member of the Committee on Clinical Pharmacology and Pharmacogenomics and the Director of the Pharmacogenetics of AntiCancer Agents Research Group Cell Line Core.

Her main research focus is the translational pharmacogenomics of anticancer agents. By systematically evaluating human genomes and their relationships to drug response and toxicity, Dr. Huang is developing clinically-useful models that predict risks for adverse reactions and non-response prior to the administration of chemotherapy.

Since the start of her post-doctoral training at the University of Chicago in 2005, Dr. Huang has published 20 peer-reviewed publications, 4 reviews, and 2 book chapters, many of which are in top-ranked journals (e.g., Proceedings of the National Academy of Science, Cancer Research, Blood, and the American Journal of Human Genetics). Dr. Huang has also successfully obtained both external and internal funding (e.g., from the National Cancer Institute, National Institute of General Medical Sciences, and the American Cancer Society), and has won many trainee awards, including the American Association for Cancer Research Merck Scholar-in-Training Award, the Aflac Scholar-in-Training Award, and the American Society for Clinical Pharmacology and Therapeutics Presidential Trainee Award.

Selected Publications from 2010 – 2011

  • Best T, Li D, Skol A, Kirchhoff T, Jackson S, Yasui Y, Bhatia S, Strong L, Domchek S, Nathanson K, Olopade O, Huang RS, Mack T, Conti D, Offit K, Cozen W, Robison L, Onel K.  Variants at 6q21 implicate PRDM1 in the etiology and therapy-induced second malignancies after Hodgkin’s lymphoma.  Nature Medicine [in press], 2011.
  • Huang S, Johnatty SE, Gamazon E,  Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J,  Australian Ovarian Cancer Study Group, Mi S, O’Donnell PH, Fraiman YS, Das S, Cox NJ, DeFazio A, Chenevix-Trench  G, Dolan ME. Germline Polymorphism Discovered via a Cell-based Genome-wide Approach Predicts Platinum Response in Ovarian Cancer. Clinical Cancer Research [in press], 2011.
  • Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME. Population differences in microRNA expression and biological implications. RNA Biol  [Epub ahead of print], 2011.
  • Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Stephanie Huang R, Eileen Dolan M. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics 21:476-488, 2011.
  • Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol 12(5):R46, 2011.
  • Ziliak D, O’Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS.Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157:265-272, 2011.
  • Gamazon ER, Im HK, O’Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther 10:472-480, 2011.
  • Stark AL, Zhang W, Zhou T, O’Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet 87:829-833, 2010.
  • Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 107:9287-9292, 2010.
  • O’Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Stephanie Huang R, Eileen Dolan M. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics 20:327-337, 2010.

Reviews/Editorials

  • Lucy A. Godley, John Cunningham, M. Eileen Dolan, R. Stephanie Huang, Sandeep Gurbuxani, Megan E. McNerney, Richard A. Larson, Hoyee Leong, Yves Lussier, Kenan Oncel, Olatoyosi Odenike, Wendy Stock, Kevin P. White and Michelle M. LeBeau.  An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Seminars in Oncology 38:215-224, 2011.

Selected Presentations

  • “Genome-wide Discovery and Clinical Validation of Pharmacogenomic Markers for Chemotherapy” Invited Speaker at the tenth (Chinese) National Forum of Pharmacology of Chemotherapeutic Drugs and Anti-infective Drugs
    Beijing, China
    September 2010
  • “Genome-wide Discovery and Clinical Validation of Pharmacogenomic Markers for Chemotherapy”
    Invited Speaker at the Personalized Cancer Therapeutics Fall Symposium, University of Chicago Comprehensive Cancer Center (UCCCC)
    Chicago, IL
    October 2010
  • “SNPs and response to Chemotherapy in Ovarian Cancer”
    Invited Speaker at the Eighth International Workshop on Pharmacodynamics of Anticancer Agents
    Hakone, Japan
    October 2010
  • “A New Era of Medicine: Personalizing Medicine”
    Invited Speaker at The Discovery & Impact dinner
    Chicago, IL
    May 2011
  • “Population-Specific MicroRNA Expression and Biological Implications for Sensitivity to Chemotherapy”
    Speaker at the American Society of Clinical Oncology International Development and Education Award (IDEA) Fellow luncheon
    Chicago, IL
    May 2011
  • “Identifying Pharmacogenomic Predictors of Tamoxifen Sensitivity using a Cell-Based Model”
    Invited Speaker for the Personalized Therapeutics Seminar series, School of Medicine, Indiana University
    Indianapolis, IN
    June 2011